Starboard Value LP underperformed peers in 2024, a year in which Jeff Smith’s activist firm was frustrated with large ...

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...

Starboard Value LP bought a new stake in shares of Pfizer in the 4th quarter valued at $407,730,000. Raymond James Financial Inc. bought a new stake in shares of Pfizer in the 4th quarter valued ...

ByInvesting.com • Oct 09, 2024 Pfizer CEO plans to meet activist investor Starboard, FT reports (Reuters) -Pfizer CEO Albert Bourla plans to meet key executives of activist hedge fund Starboard ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Reports Q4 revenue $455.024M, consensus $421.85M. “It was a solid year and fourth quarter for Green Dot (GDOT) as we accelerated revenue and ...

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

New Delhi: Pfizer on Friday said its board has approved signing a marketing and supply agreement with Mylan Pharmaceuticals for two of its brands – Ativan and Pacitane. Ativan is used for the ...